Skip to main content
Signal8

Invion Limited (IVIXF)

Sector: Drug Manufacturers - Specialty & Generic

Industry: Drug Manufacturers - Specialty & Generic

Invion Limited logo

Invion Limited

OTC:IVIXFHealthcare
Mkt Cap-
EV-
Float59.25M
O/S110.55M
Inst Own-
Net Cash/Sh-
Dilution
Historical Data
DateOpenHighLowCloseVolume
Nov 10, 20260.03690.03690.03690.03692
Nov 9, 20260.03690.03690.03690.03692
Nov 6, 20260.03690.03690.03690.03692
Nov 3, 20260.03690.03690.03690.03692
Nov 2, 20260.03690.03690.03690.03692
Oct 30, 20260.03690.03690.03690.03692
Oct 29, 20260.03690.03690.03690.03692
Oct 26, 20260.03690.03690.03690.03692
Oct 23, 20260.03690.03690.03690.03692
Oct 20, 20260.03690.03690.03690.03692
Oct 19, 20260.03690.03690.03690.03692
Oct 16, 20260.03690.03690.03690.03692
Oct 15, 20260.03690.03690.03690.03692
Oct 12, 20260.03690.03690.03690.03692
Oct 9, 20260.03690.03690.03690.03692
Oct 8, 20260.03690.03690.03690.03692
Oct 5, 20260.03690.03690.03690.03692
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
About

Invion Limited, an Australian biopharmaceutical firm currently in the clinical development phase, is dedicated to pioneering light-activated therapies for a diverse range of cancers.

Its leading therapeutic candidate, IVX-PDT, functions as a photosensitizer agent aimed at treating not only skin cancers but also various solid tumors, such as those found in the lung, prostate, ovaries, and in cases of mesothelioma.

The company engages in strategic collaborations to further its research and development efforts.

It holds an R&D agreement with the Hudson Institute of Medical Research, partnering on several projects related to the Photosoft technology for cancer treatment.

Additionally, Invion has established a research pact with the Peter MacCallum Cancer Centre to carry out pre-clinical and in-vitro studies focusing on its IVX-PDT photodynamic therapy for ano-genital cancers, including penile and anal forms. Established in 2000, Invion Limited is based in Melbourne, Australia.

Key Metrics
Market Cap--
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 110.55M shares outstanding

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ExchangeOTC
CountryAUAU
IPO Date-
Shares Outstanding110.55M
Authorized Shares
Float59.25M
52-Week Range
Volume
Average Daily Volume2

30d Avg

2

60d Avg

2

90d Avg

2

Earnings
Dividend History
No dividend history available